abbott labs takes care of that. one of the two important features of abbott labs is you look at it from the point of view of the agency. you say how formal visit? what was there left to be done? we have a whole set, a whole part of the cfr which is devoted to this. which goes, it's called jurisdictional determination from instructional guidebook. the army corps of engineers is broadening. once and make a determination, it's called the agency's official view. it stated it remains in effect for five years unless in this inch change. you say and approve the jurisdictional determination marks the culmination of a distinct process by which the corps and forms and land on whether the corps believe that covered waters are present. that doesn't sound like someone giving informal advice, and there's an appeal process. it sounds like a formal system of answered a question, which question is, are these lands wetlands, federal or not? if you get some kind of informal advice, find. you would come to a different result. i just li

. >>> in the headlines, a mega-deal announced moments ago abbott labs buying st. and stock. $85 a share. abbott expects the deal to add 21 cents per share to its earnings in 2017. 29 cents in 2018. shares of st. jude medical up 29%. abbott labs down almost 5%, by the way. world markets under pressure this morning after the bank of japan decided to stand pat and not provide additional stimulus as had been widely expected. the effect of that particularly pronounced in the yen and across currency markets. the yen soaring. it's at 1.08 on the dollar chalking up the biggest one-day gain in about five years. gdp picture is not that pretty in the u.s. economists looking for annual growth rate of .7%. half of what we saw in the fourth quarter of last year. >>> ford mots. fill phil lebeau joins us with the numbers. >> 68 cents per share. analysts expecting 48 cents per share. revenue a tad light at $38.2 billion. automotive revenue. when you look at the record first quarter for ford, trucks and suvs particularly in north america that's what's driving the results. north ame

abbott labs takes care of that. of the three important features of abbott labs is you look at it from the point of view of the agency, and you say how formal is it, what was there left to be done? in this case, we have a whole set of the cfr which is devoted to this. it's called jurisdictional determination from an instructional guide book. the army corps of engineers. once they make a determination, it is called the agency's official view. they remains in effect for five years in less conditions change. you and your brief say that the issuance of an approved jurisdictional determination marks the commendation of the distinct process by which the and forms arps landowner whether they believe it is present. that doesn't summit someone giving formal advice. the appeals process sounds like a formal system of answering a question. which question is are these lands wetlands federal or not? if you had informal advice, you would come to a different result. i just a suggested -- i have just suggested it isn't at all informa

of the high-quality mid-sized companies are going to be looking for opportunities. >> reporter: abbott labs' stock fell thursday in part over concerns st. jude hasnceen losing market share to medtronic. abbott wasn't the only company buying. its spinout advee announced a deal for cancer startup stemc t stemcentrics. investors in the biotechhe are eligible to receive additional if certain milestones are met. french giant sanofi offered an unsolicited offer for san francisco's medevation who makes a prostate cancer drug which drew nearly $2 billion in 2015 revenue. medevation stuck traded above the offer price signaling investors think a higher bid may materialize. according to credit sweet, anna fee may not be the only one interested. cellgene, roche, and astrazeneca could all take a look. all the deal affidavit gave a boost to biotech valuations across the board. nor "nightly business report," i'm meg terrell. >>> dreamworks and comcast made it official. last night we told you two companies were close to a deal. today they confirmed they are getting together in an acquisition worth $3.8 bil

jude share holders but i think it will be good for abbott labs. it's crazy. they made an extraordinary hostile bid. a very strong oncology franchise. then another anti-cancer play. i'm seeing $45 billion worth in one day. all deals seem to be dead on arrival. they are rewarded with higher prices. one more stunner. first, an amazing cancer franchise. what a horse even on an ugly day like today. i've seen much stronger quarters than the one we got this morning. it went higher although it did finish not near as high because of the icahn sell-off. gilead got slammed in after hours trading. i'm calling gilead the outlier. i don't care. it is safe to say it is better off than wits the former ceo mike pearson. i sure didn't appreciate the way left. it is in total disarray. staunching the bleeding the crucially hearing of the entire group. especially allergen which i think gets locked in. so can they go from a bull market to a raging status like so many others? here's the bottom line. we have an awful lot of signs the drought is over. so my conclusion is yes. i say i

abbott labs buying st. jude medical. that deal valued at $25 million.ot of deals going on in this space. what does it tell you about these particular deals and what they are paying? >> yeah, you know, first of all these are two massive deals in the health care space that are not related to each other, but you do have the continued activity in health care we have seen over the last two years of record transactions going on. bvie trying on, ab to get away from their biggest drug, humira, that is almost 60% of the company's revenue. they have been making this big push into cancer therapy. last year they did the deal with pharmacyclics. thett and st. jude, on other hand, different reason for the transaction. medical devices have been sucking costs. hospital groups and her customers are getting bigger. if you're someone that makes pacemakers, other cardiac devices like these two companies then you need to cut costs out of your company's. do these mergers that are going to create scale and go to your customers and compete against the other folks with a lower

among the quarterly numbers today, abbott lab, american express, united and qualcomm, on tuesday the dow climbing 49 points. the nasdaq down 19 to 4940. meanwhile the fuel economy test controversy is widening. auto maker mitsubishi addressing issues of misconduct. it says employees falsify data on vehicles. mitsubishi stock is down more than 15%. wiping $1.2 billion from its market value today. other auto makers have faced issues, including hyundai and affiliate kia motors. >>> and mcdonald's altering its classic menu items in an effort to revise business t. fast food giant testing bigger and smaller versions of its big mac in ohio and texas. they will be calling it grand mac and mac, wallace if the tests are successful, they will roll out the options nationally. back over to you. >> grand mac and mac, jr., no mac daddy for you. >> no, what itself this med july big mac? they're big. landon dowdy, live from new york. >> silicon valley chip maker intel announcing it is slashing 12,000 jobs to santa clara based company saying the job cuts will happen. they'll be phased in over the next

among some of the big names to deliver quarterly reports are abbott labs, american express, united con-- continental and qualcomm. back over to you. >> thanks for that. >>> now your nbc 10 first alert weather. >> 52 degrees. skies are clear this morning. it is getting chillier. low 50s in philadelphia but much of the area has dropped into the 40s this morning and a few areas getting closer to the 30s at this hour. your be inhood forecast is just ahead. jessica boyington is in the first alert traffic center. how's it looking out there, jessie? >> it's looking okay, bill. for the most part the majors are great. here's 309 through norristown road. i'll have updates when i come back in the next five minutes. >>> do or die. the flyers now have one more chance to save their season following an ugly loss at home on monday. you'll also hear from the family of ed snider about what happened during game three at the wells fargo center. >>> take a look at these electronic meters that neighbors in delaware are calling eye sores. we'll tell you what they tried to do to get rid of them and why city o

abbott labs, american express, united continental and qualcomm. betty? >> thank you so much. >>> find out which state's governor has declared pornography a public health hazard. >>> plus, a rare tornado caught on camera. you're watching "first look." ♪ ♪ you live life your way. we can help you retire your way, too. financial guidance while you're mastering life. from chase. so you can. financial guidance while you're mastering life. we stop arthritis pain, so you don't have to stop. because you believe in go. onward. today's the day. carpe diem. tylenol® 8hr arthritis pain has two layers of pain relief. the first is fast. the second lasts all day. we give you your day back. what you do with it is up to you. tylenol®. ♪ no, you're not ♪ yogonna watch it! ♪tch it! ♪ ♪ we can't let you download on the goooooo! ♪ ♪ you'll just have to miss it! ♪ yeah, you'll just have to miss it! ♪ ♪ we can't let you download... uh, no thanks. i have x1 from xfinity so... don't fall for directv. xfinity lets you download your shows from anywhere. i used to like that song. >>

you want to get to abbott labs for our mad dash. >> abbott labs had milestones in innovation this quartery do i point that out? because miles white is the driving force behind milestones. it was a remarkable quarter. hitting on all division cylin r cylinde cylinders. remember only 30% of this company is from the united states. this is the weak dollar play. i like nutrition. i like diagnostics. am i to place in the pantheon with alex gorski, that would be asking too much right now even though miles has been around for a lot longer for jnj, but this was a fantastic quarter and he is what i called money. remember when i said johnson & johnson had mojo? >> yes. >> abbott has money. >> is that better than mojo? >> the change guys are happy with mojo. you got to love, when you do branding, criticized the drug the bank branding on their notes -- >> oh, no, their press release. >> okay. >> found that very frustrating, yes. >> this is you need better eyes than i have. but this is miles white with miles stone. do you think that's a coincidence? no, that's brilliant marketing. >> miles' stones -- >>

onto business, major merger, abbott labs acquiring st. jude medical.companies are impacted? on the earnings front, bucking the trends of weak result in this week. social media giant request with analyst expectations, we are breaking down the earnings and telling you about the stock, it is soaring this morning. bank of japan unexpected kept policy unchanged. last night at the meeting central bank saying it wants to wait longer to see the effect of negative interest rates. nikkei average tumbling and the surprise negative move is rippling throughout markets around the world. we are looking at a lower opening for the broader averages in the u.s. joining me this morning dagen mcdowell and goergette. >> absolutely, he's the donald trump of central banking. you can't predict what he's going to do. that may be attractive but in central bank is a disaster. maria: mark huckabee with us. donald trump campaigning in indiana last night. the front runner hope to go lock up the republican nomination by securing a win in the state's upcoming primary. blake berman is

jude medical, $25 billion acquisition from abbott labs, those shares up 7%.reamworks to be acquired by comcast. medivation bringing its offer public for this company. haynes buying a big australian underwear maker and shares are being rewarded. if you look at earnings related movers and some of the highlights, you can see facebook is trading higher after they came out with earnings and sales that the estimates. paypal also beating estimates. amidst all of this news, there is a milestone to talk about. today matches the second longest bull market run that we have ever seen in the united states. tomorrow will surpass it and become the second, going all the way back to march of 2009. as we get longer and longer into this bull market, the debate rages on as to whether it is justified or not. because we are seeing it long in the tooth does not mean that it is going to end. take a look. this sort of encapsulates the debate. here you have the s&p 500 in white, the federal reserve balance sheet and purple, and the s&p 500 in blue. has this been fueled by the central

jude medical by abbott labs. $40gether today more than billion in announced deals were proposed deals in some of the cases. it has been a very busy day for us. the one that is not a done deal is the deal for medivation. let's check on the bloomberg first word news. john boehner is not hiding his contempt for ted cruz. in a speech at stanford university, the school's newspaper quotes him as calling cruz "lucifer in the flash." "i have never worked with a more miserable sob in my life." cruz responded from indiana. >> when john boehner calls the lucifer, he is not directing that it may. he is directing that at you. what he is angry with me for is nothing i said to him. i never said much of anything. what he is angry with me about is standing with the american people, energizing and encouraging house conservatives to stand with the american people and actually honor the commitments we have made. mark: boehner described trump as a golfing and texting buddy. american to get their affordable care insurance will be getting more money that spending more money next year. insurers say that has

. >>> mega medical deal, abbott labs announcing plans to buy st. jude medical for 25 million dollars. it will add to heart and neurological devices, something on behalf of st. jude that investors like that stock jumping 26%. >>> to politics and the battle between donald trump and ted cruz is centering at this hour. solely on satan. i know. satan in the hoosier state, it's all about to head to west california and, of course, we've got team fox business coverage. jeff flock in evansville, indiana, we have connell mcshane in san francisco where all three republican candidates are headed being in. we begin with a battle breaking out on the campaign trail. this time donald trump didn't actually start it. you can blame the former house speaker john boehner. last night in front of audience at stanford university, former speaker john boehner called senator ted cruz lucipher in the flesh. he did not stop there. the guy is completely unlikable. said i have democrat friends and republican friends, i get along with almost everybody but never worked with a more

don't even the emerging markets per se but companies that have exposure to the emerging markets, abbott labr whirlpool. and that's all brazil, for sure. i like to have a better balance. >> our asset allocation models are between 8% and 10% emerging market at all times, not necessarily in line with what the msci index is. we think it is not enough to get u.s. company exposure, you knee the equities to be diverse fide and capture the benefit when they start to outperform, which at some point will happen, that will mean revert. the meantime, look at brazil, scott, today. this is a market that opens down with a big gap, recovers, now up 2% or so. there is a bid for these stocks the first time in recent memory and it is nice to see. >> just to extend what josh is saying here, we also think that anybody strategic asset allocations should have emerging markets but we have to understand, this is going to be a very -- just what you pointed out with brazil, always going to be a very volatile asset class. we term it a rip van winkle, put the money in there and don't look at it every day, look at it ov

jude medical are soaring on news it's being acquired by abbott labs.otted some unusual activity in the options market before the news broke. what did you find? >> when you look at this stock, it trades by appointment. traded only about 3,000 options in the entire month of march. but then you look at monday this week, just out of the blue, somebody steps in and buys almost 2100 of the may 60 calls. now they paid $1.54 for each call. you can see them there on our heat seeker. those calls went to $20. so, in other words, if you multiply that, the 2100 that traded, basically control 210,000 shares of stock, they went from 1$1.54 to $20 that, i 300,000 investm hechlt nt. someone is going to look into this one. this is a very well timed bet just two days ahead of this announcement. >> yeah that, volume would make it seen like there is no algarythm behind the scenes. >> okay. florida governor rick scott hitting the trail in a campaign against the $15 minimum wage in california. governor scott's economic development organization launching a new radio ad that w

and abbott labs is buying st.l at a deal of $45 million, and those stocks are moving in different directions this morning. >> coming up on the halftime report, is facebook the new apple? the shares are ripping after another blowout quarter and is mark zuckerberg's company the best in tech? and plus, we will is have mohammad alairian on the set to tell us where the stocks go from here. and we will speak to michelle cabreka brar -- michelle caruso-cabrera who is going to elle the us about the iran stock exchange. and look at all of those kids around with take your kids to work day. ba back to you, kayla. >> thank you, and let's go the rick santelli at the rick san tell hly exchange. >> this morning when i looked at the inbox, i had seven e-mails talking about the fed fund futures and percentages and when the tightenings are going to occur and this not kind of in the gray, but fleshed into two places past the decimal points, and 32%, and 19.5%, and highly detail detailed. i remember back in the 1980s when the fed fun

you have abbott labs buying st. jude medical for $25 billion. that is the biggy. abbvie

abbott labs buying medical device maker st. jude medical for more than $19 billion.mcast parent of this network says nbc universal is buying dreamworks animation for $3.8 billion. >>> that's it from cnbc, first in business worldwide. real is making new friends. amazing is getting this close. real is an animal rescue. amazing is over twenty-seven thousand of them. there is only one place where real and amazing live. seaworld. real. amazing it's like a multi-purpose piece of equipment for me. the fact that you can travel with it as a laptop and use it as a drawing tool, it's the only one i need. you're all set to book a flight using your airline credit card miles. and surprise! those seats sometimes cost a ridiculous number of miles, making it really hard to book the flight you want. luckily, there's a better way... with the capital one venture card. with venture, you'll earn unlimited double miles on every purchase, every day. and when you're ready to travel, just book the flight you want, on any airline, then use your miles to cover the cost. now you're getting somew

abbott labs buying st. jude medical for $25 million.rics. that's $5.8 billion. cnbc parent company comcast buying dreamworks animation for $3.8 billion. just this morning rovi acquiring dvr maker tivo. the question is is deal-making back. joining us is the deal-maker in chief of this country, roger altman. ever-core founder. what's going on? >> remember that in january we had a huge outbreak of financial market volatility. commodity and share prices plunging. that put a chill, as it always would do, on transactions especially among public companies. if your share price is plunging, whatever one might think the textbook should say, you tend to entrench rather than look outward. it's happened since is we have recovered from that, at least as of right this minute. and confidence has returned in terms of transactions and therefore they have -- they have come back. >> right. are these transactions that we are seeing in the headlines today, do you look at them and say these were in the pipeline, these were deals that were supposed to have got

let's keep a close eye on abbott labs stock. they expect to add to earnings. wheel have an interview with ceo white. and a cross-border hostile for medivation. we have plenty in the world of health care so to speak. jim, let's start off with abbott. by the way, they also have this o'lear deal on tap. that kaem prior to them signing a confidential agreement late in february to get this deal done on st. jude. they're talking big accretion. i'm looking at a stock that is down pretty dramatically. it's a cash and share deal. so it is going to have the effect of hurting the overall value of the deal. 4675 in cash and .8708 shares of abbott. >> let's see what dan miles has to say. st. jude, they particularly lack the scale, particularly against medtronic. st. jude said over and over again it's unfair somebody can invert in our industry. they do have i think better devices. i don't know if anyone would disagree with that. >> you think st. jude has better devices? >> st. jude. you never made money betting against miles white. you don't sell abbott, you buy it. >> the

abbott labs, you can see right now trading over a third of a percent.ugh on the revenue side or raise outlook. tupperware trading down three and two thirds percent. jon: the nasdaq down by roundabout seven points. abigail doolittle at the nasdaq with a look at movers in early trading. abigail: one stock moving against nasdaq come at dish network. stock is higher after the company reported a strong first quarter. in increase in streaming subscribers that more than offset a loss in the satellite subscribers. companyffett thinks the possibly satellite business could way a downtrend in the stock chart. suggestions that moffett could prove to be right. a price target of $40 per share. one stock that has been volatile in the first few minutes of trading on earnings, intel. 1% range after the company reported an in-line first quarter announced in an 11% workforce reduction and a cfo succession plan. the company offering a second-quarter sales outlook that missed estimates. that is similar to last quarter. an event that helped to trigger a bearish cross. we cou

of abbott labs.i urged him to reconsider this plan and to keep his american workers who've really worked so hard for abbott labs for years. well, i'm sorry to report that he responded to my letter and confirmed his company's plans to terminate these american worke workers. i'm very concerned about abbott labs because they've required the employees who are losing their jobs and being laid off to sign away their right to sue or even disparage the company if they want to receive any severance pay. as a result of this agreement, congress and the american people are unable to hear directly from the employees who are affected by this decision at abbott labs. employees who are losing their jobs to wypro, an indian company that specializes in outsourcing american jobs. abbott employees have told my staff they were concerned that even if they spoke with our office about what was happening at abbott labs, they could be sued. other companies that have signed contractors with foreign outsourcing companies to rep